This program advocates for a paradigm shift from traditional glucose-centric management to early, organ-protective combination therapy in Type 2 Diabetes. Practitioners will examine the residual cardiorenal burden that persists despite optimal glycemic control and explore the synergistic mechanisms of combining foundational agents with modern organ-protective classes. By analyzing hard endpoints from recent cardiovascular and renal outcome trials, the course equips healthcare professionals with actionable implementation strategies to reduce heart failure hospitalizations and renal decline.